ClinicalTrials.gg
CompletedNCT02221141Updated Aug 20, 2024

Screening of Fabry Disease in Patients With Left Ventricular Hypertrophy Detected in Echocardiography

An observational study in Left Ventricular Hypertrophy, sponsored by Laurence Gabriel. Completed at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-20.

Sponsored by Laurence Gabriel · Observational

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
120
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to determine the prevalence in Belgium of Fabry disease in patients with unexplained hypertrophic cardiomyopathy measured by echocardiography and to determine in Fabry patients which was the most frequently initial symptom.

Actually the early diagnosis is important because a treatment exists that can prevent future complications.

02

Conditions studied

  • Left Ventricular Hypertrophy
03

In context

Hypertrophy, Left Ventricular

162 studies on the registry are indexed under Hypertrophy, Left Ventricular; 28 are open to participants now.

This study's enrollment of 120 is below the median of 198 across 60 observational studies indexed under Hypertrophy, Left Ventricular.

Browse Hypertrophy, Left Ventricular studies →

Lead sponsor

This is the only study on the registry with Laurence Gabriel as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with left ventricular hypertrophy

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • unexplained left ventricular hypertrophy

Exclusion criteria

Exclusion Criteria:

  • isolated septal hypertrophy
05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
120 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Percentage of patients with left ventricular hypertrophy who have Fabry Disease mutation

    Time frame: 1 day

07

Study locations

1 site
  • CHU Dinant-Godinne
    Yvoir, 5530, Belgium
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02221141
Lead sponsor
Laurence Gabriel
Responsible party
Laurence Gabriel (Dr Laurence GABRIEL, Centre Hospitalier Universitaire UCLouvain Namur) — Sponsor-investigator
First posted
Aug 20, 2014
Start date
Dec 2013
Primary completion
Apr 2021
Completion
Apr 2021
Last update
Aug 20, 2024
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion